Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
A phase 2 trial of Fludarabine, Bendamustine in hodgkin lymphoma, run by Tessa Therapeutics, active and no longer recruiting.
Overview
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) is a phase 2 interventional study registered as NCT04268706 by Tessa Therapeutics, with 97 participants planned, started 2021-02-01 and due to reach its primary completion in 2025-05. Interventions recorded: CD30.CAR-T, Fludarabine, Bendamustine. Conditions listed: Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Shares Bendamustine, Fludarabine.
- TrialDALY II USA/ MB-CART2019.1 for DLBCL
Shares Bendamustine, Fludarabine.
- TrialA Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl
Shares Bendamustine, Hodgkin lymphoma.
- TrialStudy of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Shares Fludarabine, Hodgkin lymphoma.
- TrialIDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Shares Fludarabine, Hodgkin lymphoma.